FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553902416> ?p ?o ?g. }

• W2553902416 abstract "Abstract Acute myeloid leukemia (AML) patients above the age of 60 or with secondary AML generally have an unfavourable outcome. The same is true for high risk myelodysplastic syndrome (MDS) patients ineligible to bone marrow transplantation. Indeed, in spite of an improved CR rate after intensive chemotherapy (about 60–65%), median CR duration and survival remain short (9–12 months in most studies), due to early relapses. (Sekeres MA et al.: Curr Opin Oncol2002;14:24–30. Verbeek W et al.: Ann Hematol2001;80:499–509). On the basis of our previous clinical trials with differentiative agents + low dose chemotherapy in MDS/AML patients unsuitable to intensive treatments, (Ferrero D et al.: Leuk Res1996;20:867–876; Haematologica2004;89:619–620), we adopted the same strategy as a post-remission maintenance therapy to patients with AML or MDS at high risk of relapse and ineligible to allogeneic transplant. Thirty-six patients (27 AML and 9 high risk MDS) who had obtained a CR after different schemes of intensive chemotherapy were scheduled to receive the maintenance treatment with 13-cis-retinoic acid (20–40 mg/day) + 1,25-di-hydroxy-vitamin D3 (1 microgram /day) in association to intermittent, low dose chemotherapy: 6-thioguanine 40 mg/day x 21 days every 5 weeks, alternated every 2–3 months, in 24 patients, to a 14 day course of ARA-C 8 mg/m2 s.c. x 2/day + 6-mercaptopurine 50 mg/day. Patients’ median age was 64 years (range 27–76), with only 9 below the age of 60. Cytogenetic analysis was performed successfully in 27 cases, and an unfavourable karyotype was found in 10. All patients presented at least one poor prognosis determinant, including age >60 (27), previous AML relapse after autologous BMT (1), therapy-related disease (5), AML secondary to MDS (7), resistance to 1st induction therapy (4), hyperleukocytosis (8), RAEB-2 (8), abnormal karyotype (10). Twenty six had received 1 - 4 courses of consolidation treatment, including autologous stem cell transplantation in 2 MDS patients, before starting the maintenance program. Three patients underwent a very early relapse before maintenance start and 1 patient refused to prosecute the therapy after the first 2 months. The other 32 patients received the treatment as outpatients, with good tolerance and no major toxicity, until relapse, death or 4 years of continuous CR. After a median follow up for alive patients of 23 months (6–76), median disease-free (dfs) and overall survival, based on intention to treat analysis are 22 (1–74+) and 23 (5–76+) months, respectively, with a 28% 4 year actuarial survival. Inclusion of ARA-C in the maintenance treatment did not significantly prolong CR duration. The 17 patients with a normal karyotype enjoyed better median dfs (43 months) and overall survival (50,5 months) compared to the 10 patients with abnormal cytogenetics (12,5 and 15,5 months respectively); however, the differences are not significant, probably due to sample exiguity. In conclusion, our patients evidenced quite longer dfs and overall survival than expected from literature data on AML/MDS patients with similar features. However some late relapses (after 3–4 years) occurred. Therefore, our maintenance program seems worthy to be evaluated on larger casistics in randomised trials." @default.
• W2553902416 created "2016-11-30" @default.
• W2553902416 creator A5011678278 @default.
• W2553902416 creator A5015546827 @default.
• W2553902416 creator A5018139001 @default.
• W2553902416 creator A5018509851 @default.
• W2553902416 creator A5036792204 @default.
• W2553902416 creator A5057804347 @default.
• W2553902416 creator A5077328355 @default.
• W2553902416 creator A5086305084 @default.
• W2553902416 date "2005-11-16" @default.
• W2553902416 modified "2023-09-30" @default.
• W2553902416 title "A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients." @default.
• W2553902416 doi "https://doi.org/10.1182/blood.v106.11.4614.4614" @default.
• W2553902416 hasPublicationYear "2005" @default.
• W2553902416 type Work @default.
• W2553902416 sameAs 2553902416 @default.
• W2553902416 citedByCount "0" @default.
• W2553902416 crossrefType "journal-article" @default.
• W2553902416 hasAuthorship W2553902416A5011678278 @default.
• W2553902416 hasAuthorship W2553902416A5015546827 @default.
• W2553902416 hasAuthorship W2553902416A5018139001 @default.
• W2553902416 hasAuthorship W2553902416A5018509851 @default.
• W2553902416 hasAuthorship W2553902416A5036792204 @default.
• W2553902416 hasAuthorship W2553902416A5057804347 @default.
• W2553902416 hasAuthorship W2553902416A5077328355 @default.
• W2553902416 hasAuthorship W2553902416A5086305084 @default.
• W2553902416 hasConcept C126322002 @default.
• W2553902416 hasConcept C141071460 @default.
• W2553902416 hasConcept C2776694085 @default.
• W2553902416 hasConcept C2778283404 @default.
• W2553902416 hasConcept C2778336483 @default.
• W2553902416 hasConcept C2780007613 @default.
• W2553902416 hasConcept C2780817109 @default.
• W2553902416 hasConcept C2911091166 @default.
• W2553902416 hasConcept C71924100 @default.
• W2553902416 hasConcept C90924648 @default.
• W2553902416 hasConceptScore W2553902416C126322002 @default.
• W2553902416 hasConceptScore W2553902416C141071460 @default.
• W2553902416 hasConceptScore W2553902416C2776694085 @default.
• W2553902416 hasConceptScore W2553902416C2778283404 @default.
• W2553902416 hasConceptScore W2553902416C2778336483 @default.
• W2553902416 hasConceptScore W2553902416C2780007613 @default.
• W2553902416 hasConceptScore W2553902416C2780817109 @default.
• W2553902416 hasConceptScore W2553902416C2911091166 @default.
• W2553902416 hasConceptScore W2553902416C71924100 @default.
• W2553902416 hasConceptScore W2553902416C90924648 @default.
• W2553902416 hasLocation W25539024161 @default.
• W2553902416 hasOpenAccess W2553902416 @default.
• W2553902416 hasPrimaryLocation W25539024161 @default.
• W2553902416 hasRelatedWork W1966831768 @default.
• W2553902416 hasRelatedWork W2043740576 @default.
• W2553902416 hasRelatedWork W2077004848 @default.
• W2553902416 hasRelatedWork W2085359490 @default.
• W2553902416 hasRelatedWork W2088520561 @default.
• W2553902416 hasRelatedWork W2092471844 @default.
• W2553902416 hasRelatedWork W2108413184 @default.
• W2553902416 hasRelatedWork W2470056964 @default.
• W2553902416 hasRelatedWork W2553902416 @default.
• W2553902416 hasRelatedWork W4229033146 @default.
• W2553902416 isParatext "false" @default.
• W2553902416 isRetracted "false" @default.
• W2553902416 magId "2553902416" @default.
• W2553902416 workType "article" @default.